258 related articles for article (PubMed ID: 15136407)
21. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
Raz-Pasteur A; Shasha D; Paul M
Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
[TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
[TBL] [Abstract][Full Text] [Related]
23. How Antibiotics Should be Prescribed to Hospitalized Elderly Patients with Community-Acquired Pneumonia.
Arnold FW
Drugs Aging; 2017 Jan; 34(1):13-20. PubMed ID: 27928779
[TBL] [Abstract][Full Text] [Related]
24. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
[TBL] [Abstract][Full Text] [Related]
25. Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials.
Niederman MS; Chang JR; Stewart J; Asche CV; Lavin B; Nusrat R; Sullivan SD
Curr Med Res Opin; 2004 Jul; 20(7):969-80. PubMed ID: 15265241
[TBL] [Abstract][Full Text] [Related]
26. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
[TBL] [Abstract][Full Text] [Related]
27. Antimicrobial therapy of community-acquired pneumonia.
File TM; Niederman MS
Infect Dis Clin North Am; 2004 Dec; 18(4):993-1016, xi. PubMed ID: 15555836
[TBL] [Abstract][Full Text] [Related]
28. The role of new therapies for severe community-acquired pneumonia.
Restrepo MI; Anzueto A
Curr Opin Infect Dis; 2006 Dec; 19(6):557-64. PubMed ID: 17075331
[TBL] [Abstract][Full Text] [Related]
29. Worldwide guidelines for respiratory tract infections: community-acquired pneumonia.
Dalhoff K
Int J Antimicrob Agents; 2001; 18 Suppl 1():S39-44. PubMed ID: 11574194
[TBL] [Abstract][Full Text] [Related]
30. Principles of Antibiotic Management of Community-Acquired Pneumonia.
Bender MT; Niederman MS
Semin Respir Crit Care Med; 2016 Dec; 37(6):905-912. PubMed ID: 27960214
[TBL] [Abstract][Full Text] [Related]
31. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host.
Vergis EN; Yu VL
Semin Respir Infect; 1997 Dec; 12(4):322-8. PubMed ID: 9436959
[TBL] [Abstract][Full Text] [Related]
32. Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.
Pereira JM; Gonçalves-Pereira J; Ribeiro O; Baptista JP; Froes F; Paiva JA
J Crit Care; 2018 Feb; 43():183-189. PubMed ID: 28915392
[TBL] [Abstract][Full Text] [Related]
33. Advances in antibiotic therapy for community-acquired pneumonia.
Viasus D; Garcia-Vidal C; Carratalà J
Curr Opin Pulm Med; 2013 May; 19(3):209-15. PubMed ID: 23422416
[TBL] [Abstract][Full Text] [Related]
34. Monotherapy or combination therapy for hospitalized patients with community-acquired pneumonia: not yet the end of the story?
Laterre PF
Clin Infect Dis; 2008 May; 46(10):1510-2. PubMed ID: 18419483
[No Abstract] [Full Text] [Related]
35. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home.
Chen JI; Slater LN; Kurdgelashvili G; Husain KO; Gentry CA
Ann Pharmacother; 2013 Jan; 47(1):9-19. PubMed ID: 23324506
[TBL] [Abstract][Full Text] [Related]
36. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.
File TM; Tan JS
Drugs; 2003; 63(2):181-205. PubMed ID: 12515565
[TBL] [Abstract][Full Text] [Related]
37. Antibiotic stewardship in community-acquired pneumonia.
Viasus D; Vecino-Moreno M; De La Hoz JM; Carratalà J
Expert Rev Anti Infect Ther; 2017 Apr; 15(4):351-359. PubMed ID: 28002979
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial drug prescribing patterns for community-acquired pneumonia in hospitalized patients: A retrospective pilot study from New Delhi, India.
Kotwani A; Kumar S; Swain PK; Suri JC; Gaur SN
Indian J Pharmacol; 2015; 47(4):375-82. PubMed ID: 26288468
[TBL] [Abstract][Full Text] [Related]
39. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.
File TM; Garau J; Blasi F; Chidiac C; Klugman K; Lode H; Lonks JR; Mandell L; Ramirez J; Yu V
Chest; 2004 May; 125(5):1888-901. PubMed ID: 15136404
[TBL] [Abstract][Full Text] [Related]
40. Macrolide Resistance in Cases of Community-Acquired Bacterial Pneumonia in the Emergency Department.
Haran JP; Volturo GA
J Emerg Med; 2018 Sep; 55(3):347-353. PubMed ID: 29789175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
